Ritika Kundra

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Integrated Clinicogenomic Risk Modeling for Metachronous Second Primary Cancers

  medRxiv · 2026-06-22

• IDH1 Mutations Are Associated with Favorable Outcomes in Prostate Cancer.

  PubMed · 2026-05-13

• Cancer type-specific variation in patterns of driver alterations across 50,000 tumors

  Cancer Cell · 2026-04-18

• Abstract 5222: Multifactorial risks for multiple primary cancers

  Cancer Research · 2026-04-03

• Abstract 2498: OncoKB™, MSK’s precision oncology knowledge base: 2025 updates

  Cancer Research · 2026-04-03

• Abstract 4097: cBioPortal for cancer genomics

  Cancer Research · 2026-04-03

• Cancer type-specific variation in patterns of driver alterations across 50,000 tumors

  Cancer Cell · 2026-03-26 · 2 citations

• supplementary legend1 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention

  2025-11-25

• Figure S1 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention

  2025-11-25

• Supplementary Data1 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention

  2025-11-25

• Figure s2 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention

  2025-11-25

• DH1 and IDH2 Mutations in prostate cancer

  European Urology Open Science · 2025-11-01

• Ongoing genome doubling shapes evolvability and immunity in ovarian cancer

  Nature · 2025-07-16 · 36 citations

• Supplementary Table S2 from Multimodal Spatial Profiling Reveals Immune Suppression and Microenvironment Remodeling in Fallopian Tube Precursors to High-Grade Serous Ovarian Carcinoma

  2025-06-03

• Supplementary Table S9 from Multimodal Spatial Profiling Reveals Immune Suppression and Microenvironment Remodeling in Fallopian Tube Precursors to High-Grade Serous Ovarian Carcinoma

  2025-06-03

• Supplementary Table S10 from Multimodal Spatial Profiling Reveals Immune Suppression and Microenvironment Remodeling in Fallopian Tube Precursors to High-Grade Serous Ovarian Carcinoma

  2025-06-03

• Supplementary Table S1 from Multimodal Spatial Profiling Reveals Immune Suppression and Microenvironment Remodeling in Fallopian Tube Precursors to High-Grade Serous Ovarian Carcinoma

  2025-06-03

• Supplementary Table S8 from Multimodal Spatial Profiling Reveals Immune Suppression and Microenvironment Remodeling in Fallopian Tube Precursors to High-Grade Serous Ovarian Carcinoma

  2025-06-03

• Supplementary Methods from Multimodal Spatial Profiling Reveals Immune Suppression and Microenvironment Remodeling in Fallopian Tube Precursors to High-Grade Serous Ovarian CarcinomaPreprint

  2025-06-03

• Supplementary Table S6 from Multimodal Spatial Profiling Reveals Immune Suppression and Microenvironment Remodeling in Fallopian Tube Precursors to High-Grade Serous Ovarian Carcinoma

  2025-06-03